Leuprorelin Acetate for Spinal and Bulbar Muscular Atrophy: A Systematic Review of Clinical Efficacy, Long-Term Outcomes, and Safety Considerations.
Leuprorelin may slow long-term functional decline in SBMA, particularly if treatment starts early, but short-term benefits are not evident.
Where it sits
this study against the rest of the leuprorelin corpusSummary and findings
This systematic review evaluated the efficacy and safety of leuprorelin acetate in patients with spinal and bulbar muscular atrophy (SBMA). Eleven studies were included, comprising eight efficacy studies with 460 patients. Leuprorelin was associated with a slower decline in certain functional scores and improved biochemical markers.
Abstract
Spinal and bulbar muscular atrophy (SBMA; Kennedy disease) is a rare X-linked neuromuscular disorder caused by a CAG repeat expansion in the androgen receptor gene. Leuprorelin acetate, a luteinizing hormone-releasing hormone agonist, suppresses androgen signaling and is approved for SBMA-associated dysphagia in Japan; however, evidence regarding efficacy remains heterogeneous. PubMed and Embase were searched from inception through June 18, 2026, for studies evaluating leuprorelin in genetically confirmed SBMA. Randomized trials, observational cohorts, natural history-controlled studies, extension studies, and safety case reports were included, and findings were synthesized narratively because of substantial heterogeneity. Eleven studies met inclusion criteria, including eight efficacy studies (460 patients) and three safety-focused case reports. Leuprorelin reduced pathogenic androgen receptor accumulation and improved biochemical markers, including serum creatine kinase and creatinine decline. Although neither pivotal randomized trial demonstrated significant short-term functional improvement at 48 weeks, longer-term studies showed slower decline in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Limb Norris, and Norris Bulbar scores and improved event-free survival from pneumonia and death. Benefits were greatest with earlier treatment, particularly disease duration < 10 years. Leuprorelin was generally well tolerated; common adverse effects included hot flushes, sexual dysfunction, and decreased bone mineral density. Leuprorelin may slow long-term functional deterioration in SBMA, with greater benefit following early initiation and prolonged treatment.
Background
This paper addresses the clinical question of the efficacy of leuprorelin acetate in treating spinal and bulbar muscular atrophy (SBMA), a rare neuromuscular disorder. Previous studies have shown mixed results regarding the effectiveness of leuprorelin in this context. Understanding its potential benefits and safety profile is crucial for clinicians considering treatment options for SBMA.
Methods
The review included randomized trials, observational cohorts, natural history-controlled studies, extension studies, and safety case reports. A total of 11 studies were analyzed, comprising 460 patients. The studies evaluated various outcomes related to functional decline and biochemical markers, with a focus on both efficacy and safety.
Results
The review found that neither pivotal randomized trial demonstrated significant short-term functional improvement at 48 weeks. However, longer-term studies indicated a slower decline in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores. Specific p-values and confidence intervals were not reported in the abstract.
Interpretation
The findings suggest that while leuprorelin may not provide short-term benefits, it could potentially slow long-term functional decline in SBMA patients, especially if treatment is initiated early. However, the lack of significant short-term improvement and the heterogeneity of the included studies limit the strength of these conclusions. Practitioners should consider these factors when evaluating leuprorelin for SBMA.
Key findings
- Neither pivotal randomized trial demonstrated significant short-term functional improvement at 48 weeks.
- Longer-term studies showed slower decline in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores.
- Improved event-free survival from pneumonia and death was noted.
- Common adverse effects included hot flushes, sexual dysfunction, and decreased bone mineral density.
Limitations
- Heterogeneous studies included.
- Neither pivotal trial showed significant short-term improvement.
- Long-term benefits are uncertain due to lack of consistent data.
- Common adverse effects may impact patient quality of life.